verapamil has been researched along with Extensively Drug-Resistant Tuberculosis in 2 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
Extensively Drug-Resistant Tuberculosis: Tuberculosis resistant to ISONIAZID and RIFAMPIN and at least three of the six main classes of second-line drugs (AMINOGLYCOSIDES; polypeptide agents; FLUOROQUINOLONES; THIOAMIDES; CYCLOSERINE; and PARA-AMINOSALICYLIC ACID) as defined by the CDC.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors | Studies |
---|---|
Dixit, PP | 2 |
Thore, SN | 1 |
Perveen, S | 1 |
Kumari, D | 1 |
Singh, K | 1 |
Sharma, R | 1 |
1 review available for verapamil and Extensively Drug-Resistant Tuberculosis
Article | Year |
---|---|
Tuberculosis drug discovery: Progression and future interventions in the wake of emerging resistance.
Topics: Antitubercular Agents; Diarylquinolines; Drug Therapy, Combination; Ethambutol; Extensively Drug-Res | 2022 |
1 other study available for verapamil and Extensively Drug-Resistant Tuberculosis
Article | Year |
---|---|
Hybrid triazoles: Design and synthesis as potential dual inhibitor of growth and efflux inhibition in tuberculosis.
Topics: Antitubercular Agents; Cells, Cultured; Chemistry Techniques, Synthetic; Drug Design; Drug Evaluatio | 2016 |